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Clinical Question 
Does raloxifene (Evista) prevent fractures in postmenopausal women with osteoporosis? 
Evidence-Based Answer 
Raloxifene (60 mg daily for three years) will prevent one vertebral fracture, including 
asymptomatic fractures, for every 46 postmenopausal women with osteoporosis or presence of 
previous vertebral fractures. Raloxifene has not been shown to prevent nonvertebral fractures. It 
is unclear if longer duration of treatment is warranted, or whether this risk reduction is sustained 
after discontinuation of treatment. [Strength of recommendation: A, based on systematic reviews 
of randomized controlled trials (RCTs)] 
Evidence Summary 
Raloxifene is a selective estrogen receptor modulator with tissue-specific estrogen receptor 
effects. Raloxifene inhibits bone resorption and may decrease breast cancer risk. 
A systematic review1 of osteoporosis therapies summarized the results of two RCTs.2,3 The 
largest of these studies is the Multiple Outcomes of Raloxifene Evaluation (MORE) study, an 
RCT of 7,705 postmenopausal women who met the World Health Organization criteria for 
osteoporosis based on low bone mineral density (T-score lower than -2.5)1 or presence of 
previous vertebral fracture. The MORE study found a reduction in the risk of vertebral fracture 
for women with osteoporosis after three years of treatment with 60 mg of raloxifene daily 
(number needed to treat [NNT] for three years: 46), as well as in a subgroup of women with 
osteopenia (bone mineral density T-score lower than -1.5)1 and pre-existing fractures (NNT: 16). 
Results with 60 and 120 mg doses of raloxifene were not significantly different. The incident 
vertebral fractures were radiographically determined at 
24- and 36-month visits, or at any time if the women developed symptoms of vertebral fractures. 
The study did not report whether there was a difference in clinically apparent vertebral fractures. 
Nonvertebral fractures were determined by interview at six-month intervals.2 
A second large RCT4 included in the systematic review1 showed no significant effect of 
raloxifene; however, because it was designed for breast cancer prevention and measured fracture 
prevention only as a secondary outcome, the inclusion criteria did not include osteoporosis risk 
factors and may have led to an uneven distribution in treatment and placebo groups. 
Asymptomatic vertebral fractures may have been undercounted because fractures were only 
diagnosed by patient self-report.1 A 12-month blinded extension of the MORE study showed 
that raloxifene (60 or 120 mg) continued to decrease the cumulative relative risk of new vertebral 
fractures in women with osteoporosis through year 4.5 A smaller, one-year RCT3 confirmed that 
raloxifene significantly decreased asymptomatic vertebral fractures when the fractures were 
diagnosed using strict radiographic criteria. Raloxifene had no significant effect on symptomatic 
vertebral fractures or on nonvertebral fractures. The ratio of treatment group responders to 
control group responders was 0.9 (95 percent confidence interval: 0.8 to 1.1). This smaller RCT 
was limited by sample size and shorter duration of monitoring. 
Side effects from raloxifene include venous thromboembolism (number needed to harm [NNH] 
after three years: 161), hot flashes (NNH: 22), and leg cramps (NNH: 32). Raloxifene may 
decrease the risk of breast cancer (NNT: 93).2,6 
Recommendations from Others 
The American College of Obstetricians and Gynecologists and the American Association of 
Clinical Endocrinologists recommend raloxifene as an acceptable option for the treatment of 
women with postmenopausal osteoporosis and risk factors for fracture, and for women in whom 
nonpharmacologic preventive measures have not stopped continued bone loss or low-trauma 
fractures.7,8 Other therapies may be more effective or preferred in a given clinical situation (see 
Clinical Commentary). Non-pharmaceutical preventive options for osteoporosis include weight-
bearing exercise, abstaining from tobacco, intake of calcium and vitamin D, and using safety 
measures to decrease fractures caused by falls or accidents.7 
Clinical Commentary 
From a clinical standpoint, the more interesting question might be when to use raloxifene as 
opposed to other medications for the prevention of fractures in postmenopausal women with 
osteoporosis or pre-existing fractures. While raloxifene, bisphosphonates, calcitonin, and 
calcium plus vitamin D all significantly reduce vertebral fractures, only the bisphosphonates and 
calcium plus vitamin D also lower the risk of hip fractures in women with osteoporosis or 
institutionalized women, respectively.9,10 The discontinuation rate for bisphosphonates because 
of gastrointestinal side effects is significantly higher compared with raloxifene. For those who 
have gastrointestinal problems, raloxifene is a good alternative.11 Women with a medical history 
including venous thromboembolism who are immobilized for prolonged periods, or who receive 
hormone therapy should not take raloxifene because of an increased risk of venous 
thromboembolic events. The decision to continue raloxifene treatment beyond three years 
depends on the patient's experience of side effects and her desire to continue raloxifene for its 
benefit in reducing breast cancer risk.6 
The injectable parathyroid hormone teriparatide is expensive and more difficult to administer, 
but is generally well tolerated and does reduce the risk of both vertebral and nonvertebral 
fractures in postmenopausal women with prior vertebral fractures.12 The use of estrogen-only 
therapy and estrogen-plus-progestin therapy for the prevention of bone loss after menopause 
have both fallen out of favor since the Women's Health Initiative reported that the overall health 
risks are equivalent to the benefits for estrogen-only therapy and that the risks exceed the 
benefits for estrogen-plus-progestin therapy.13,14 Although somewhat less effective, calcitonin 
nasal spray is an alternative for the prevention of vertebral fractures in osteoporotic women who 
cannot tolerate or do not wish to take estrogen-only therapy, estrogen-plus-progestin therapy, 
bisphosphonates, or raloxifene.10 
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